Carasent Valuation
Is CARA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CARA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CARA (NOK20) is trading below our estimate of fair value (NOK34.92)
Significantly Below Fair Value: CARA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CARA?
Key metric: As CARA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CARA's PS Ratio? | |
|---|---|
| PS Ratio | 5.5x |
| Sales | NOK 264.80m |
| Market Cap | NOK 1.45b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.3x |
| Enterprise Value/EBITDA | -91.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CARA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.8x | ||
NORDH Nordhealth | 5.8x | 16.7% | NOK 3.0b |
OMDA Omda | 1.5x | 6.9% | NOK 629.5m |
CONTX ContextVision | 2.9x | 2.7% | NOK 369.8m |
MEDI Medistim | 4.8x | 3.2% | NOK 2.5b |
CARA Carasent | 5.5x | 18.6% | NOK 1.4b |
Price-To-Sales vs Peers: CARA is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (3.8x).
Price to Sales Ratio vs Industry
How does CARA's PS Ratio compare vs other companies in the European Healthcare Services Industry?
| 6 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: CARA is expensive based on its Price-To-Sales Ratio (5.5x) compared to the European Healthcare Services industry average (2.3x).
Price to Sales Ratio vs Fair Ratio
What is CARA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.5x |
| Fair PS Ratio | 11.4x |
Price-To-Sales vs Fair Ratio: CARA is good value based on its Price-To-Sales Ratio (5.5x) compared to the estimated Fair Price-To-Sales Ratio (11.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | NOK 20.00 | NOK 26.00 +30.0% | 4.2% | NOK 27.00 | NOK 24.50 | n/a | 3 |
| Nov ’25 | NOK 19.90 | NOK 26.75 +34.4% | 0.9% | NOK 27.00 | NOK 26.50 | n/a | 2 |
| Oct ’25 | NOK 18.00 | NOK 25.75 +43.1% | 2.9% | NOK 26.50 | NOK 25.00 | n/a | 2 |
| Sep ’25 | NOK 18.90 | NOK 25.75 +36.2% | 2.9% | NOK 26.50 | NOK 25.00 | n/a | 2 |
| Aug ’25 | NOK 17.80 | NOK 25.75 +44.7% | 2.9% | NOK 26.50 | NOK 25.00 | n/a | 2 |
| Jul ’25 | NOK 18.20 | NOK 25.75 +41.5% | 2.9% | NOK 26.50 | NOK 25.00 | n/a | 2 |
| Jun ’25 | NOK 18.45 | NOK 25.75 +39.6% | 2.9% | NOK 26.50 | NOK 25.00 | n/a | 2 |
| May ’25 | NOK 18.65 | NOK 25.75 +38.1% | 2.9% | NOK 26.50 | NOK 25.00 | n/a | 2 |
| Apr ’25 | NOK 11.52 | NOK 26.50 +130.0% | 5.7% | NOK 28.00 | NOK 25.00 | n/a | 2 |
| Mar ’25 | NOK 11.20 | NOK 26.50 +136.6% | 5.7% | NOK 28.00 | NOK 25.00 | n/a | 2 |
| Feb ’25 | NOK 10.32 | NOK 26.50 +156.8% | 5.7% | NOK 28.00 | NOK 25.00 | n/a | 2 |
| Jan ’25 | NOK 11.06 | NOK 26.50 +139.6% | 5.7% | NOK 28.00 | NOK 25.00 | n/a | 2 |
| Dec ’24 | NOK 10.32 | NOK 26.50 +156.8% | 5.7% | NOK 28.00 | NOK 25.00 | n/a | 2 |
| Nov ’24 | NOK 13.02 | NOK 29.00 +122.7% | 3.4% | NOK 30.00 | NOK 28.00 | NOK 19.90 | 2 |
| May ’24 | NOK 15.96 | NOK 37.00 +131.8% | 5.4% | NOK 39.00 | NOK 35.00 | NOK 18.65 | 2 |
| Apr ’24 | NOK 15.80 | NOK 37.00 +134.2% | 5.4% | NOK 39.00 | NOK 35.00 | NOK 11.52 | 2 |
| Mar ’24 | NOK 16.00 | NOK 37.00 +131.3% | 5.4% | NOK 39.00 | NOK 35.00 | NOK 11.20 | 2 |
| Feb ’24 | NOK 16.14 | NOK 38.00 +135.4% | 2.6% | NOK 39.00 | NOK 37.00 | NOK 10.32 | 2 |
| Jan ’24 | NOK 16.98 | NOK 38.00 +123.8% | 2.6% | NOK 39.00 | NOK 37.00 | NOK 11.06 | 2 |
| Dec ’23 | NOK 17.62 | NOK 38.00 +115.7% | 2.6% | NOK 39.00 | NOK 37.00 | NOK 10.32 | 2 |
| Nov ’23 | NOK 18.44 | NOK 40.50 +119.6% | 8.6% | NOK 44.00 | NOK 37.00 | NOK 13.02 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.